risk of suicide attempts in young people -A Danish observational register-based historical cohort study, using propensity score. Nord J Psychiatry 2015;Early Online:1-9.
S elective serotonin reuptake inhibitors (SSRIs) are a group of antidepressant drugs licensed for treatment of depression and certain anxiety disorders. The relationship between SSRIs and the risk of suicide in young people has been subject to considerable public attention, as some studies have found a weak, but signifi cant, association between taking SSRIs and an increased risk of suicidal behaviour.
This association has been the subject of a number of meta-analyses on paediatric randomized trials. A metaanalysis performed by Mosholder and Willy (1) included 22 randomized short-term placebo-controlled paediatric trials, involving nine different antidepressant drugs. They estimated the serious suicide attempts incidence rate ratio to be 1.89 (95% CI 1.18 -3.04) for the group exposed to the active drug, compared to placebo. No completed suicides were found (1). Another meta-analysis of suicidality risk (suicidal ideation and behaviour), performed by Hammad and colleagues, estimated the risk ratio for SSRIs in depression paediatric trials to be 1.66 (95% CI: 1.02 -2.68) compared to placebo. They found no suicides either (2). A third meta-analysis of the impact of SSRIs on the risk of suicide ideation and attempts analysed the impact on three different indications for drugs (major depressive disorder, obsessive -compulsive disorder (OCD) and non-OCD anxiety disorders). They found a signifi cant pooled overall risk ratio of 1.7 (95% CI: 1.1 -2.7) for SSRIs compared to placebo (3). A meta-analysis performed SSRIs might raise risk for suicide attempts in young people, and if yes, in which period is the risk the highest? This paper will also include a discussion on the use of a pseudo-randomized (propensity score method) design to test the hypothesis.
Method

Population and follow-up period
Complete birth-cohort of every individual born in 1983 -1989 and living in Denmark has been followed from birth or immigration and until fi rst registered suicide attempt, death, emigration or end of follow-up (31 December 2011). Individuals who immigrated back into Denmark were not re-included in the study. We included data on two generations: data on the birth-cohort and data on their parents.
Factors
DATA
We used seven longitudinal (historical) Danish registers and data from the period 1977 -2011. The data were merged by using the unique civil registration number (CPR number) every Danish citizen has (12). We used data from the Danish Fertility Database (13), the Register of Causes of Death (14) , the National Patient Register (15) , the Danish Psychiatric Central Register (16) the Register of Families and Households, the Register of Unemployment and the Danish National Prescription Registry (17). OUTCOME First registered suicide attempt was the primary outcome. In keeping with previous studies (18 -20), a suicide attempt was defi ned (with ICD-10) as: contact with a somatic department when: the reason for contact was coded E4 (suicide attempts), • and the diagnostic code was one of the following: S617 -S619 (open wound of wrist and hand), T36x -T60x, T65 (poisoning/toxic effects by drug, substances etc.), and X60x -X84x (intentional self-harm), or a psychiatric disorder (F-code) as primary diagnosis, • and a diagnostic code of T36x -T50x (poisoning by drugs), T52x -T60x (poisoning effects by substances), S51x (wound of forearm), S55x (injury of blood vessels at forearm), S59x (other injuries of forearm), S61x (wound of wrist and hand), S65x (injury of blood vessels at wrist and hand) or S69x (other injuries of wrist and hand) as the secondary diagnosis, or contact with a psychiatric department when:
given a diagnostic code of X60x -X84x (suicide attempt).
• EXPOSURE For each individual, every prescription of SSRIs redeemed at any Danish pharmacy in the period 1 January 1995 to by Stone and colleagues found that association between risk of suicidality and antidepressants was strongly age dependent, such that raised risk was only seen among adults under 25 (4). Suicide is relatively rare in young people, including depressed young people, but is still among the leading causes of death (5). This is why estimation of the impact of SSRIs on suicide risk in randomized trials can be difficult, as a high number of exposed and unexposed are needed in order to show signifi cant associations. Observational studies can provide this and have therefore been used. The disadvantage of observational studies is that individuals are not randomized to SSRI treatment, and the obvious differences between SSRI users and non-users bias results. A review of six observational studies performed by Dudley and colleagues found no evidence to support the hypothesis that SSRIs raise the risk of suicide in young people (6). Another systematic review followed by a meta-analysis found that SSRIs did increase the risk (OR 1.92, 95% CI 1.51 -2.44) of suicide and suicide attempts in depressed young people, but decreased the risk in adults. This meta-analysis was based on eight studies involving 200,000 depressed patients and was performed by Barbui and colleagues (7) .
An original study carried out by Jick and colleagues of 555 cases and 2062 controls found a signifi cantly increased risk of suicidal behaviour in the fi rst 9 days after being prescribed antidepressants. The study estimated the risk ratio for that period to be 4.07 (95% CI 2.89 -5.74) (8).
The literature provides us with some indications that SSRIs might slightly increase the risk of suicide ideation and suicide attempts in children and adolescents. Their impact on completed suicides is not well-established. As suicidal behaviour is a well-known part of depression, it is diffi cult to distinguish whether the impact on risk is from the drug (SSRIs) or from the indication for the drug (e.g. depression). In observational studies the imbalance in the underlying risk profi le for SSRI users and SSRI non-users might bias results, as individuals are not randomized to SSRI treatment. In observational studies it is necessary to deal with this " confounding by indication " problem. Including a propensity score in the analysis is an attempt to reduce this problem, if the propensity score is modelled well (9).
It is well-known that treatment may have an early stimulating effect, i.e. increasing the risk that a depressed individual might act on suicidal impulses before the therapy (or anti-depressant) effect materializes (10). This drive-mood dissociation might also be present in SSRIs treatment of young people and might raise the risk of suicidal behaviour in the early phase of the treatment (11).
By using the detailed linkage opportunities afforded by Denmark ' s rich series of health, social and economic registers and an observational design, this study has aimed to answer the following two questions: is there indication that (county), death of parent, parental level of income, parental suicide attempt, parental use of psychopharmacological drugs, parents not living together, parental contact to mental health department and all kinds of parental offences, as independent variables. All the factors were coded as non-time-dependent dichotomy factors (yes/no) and we only included information that was collected prior to the fi rst redeemed prescription on SSRIs. Many of the factors are associated with SSRIs and risk of suicide attempts (21).
THE PROPENSITY SCORE (PS)
Because the allocation of treatment (SSRIs) is not random, we try to reduce bias in estimated effect, by including the above-mentioned propensity score (PS) in our analysis. Whether actually receiving the treatment or not, the logistic regression model returns an estimate of the probability of being allocated to treatment. The study participants were grouped into 50 mutually exclusive strata according to the PS value, so that individuals in a specifi c stratum have almost the same probability of redeeming a prescription no matter whether they actually redeem a prescription or not. A detailed description of the propensity score method is to be found in Williamson et al. (22) . We assessed the predictive ability to distinguish between SSRI user and non-user, and for this we 31 December 2011, and prescribed by the primary or secondary health care section, was included in the analysis. We used the ATC code (N06AB) to identify prescriptions of SSRIs. All the prescriptions were coded into three different variations of using SSRIs: previous SSRI prescriptions (yes/no); fi rst prescription of SSRIs (yes/no) coded as a time-varying factor, and prescribed SSRIs (yes/no) coded as time-varying factor for every quarter of the year. SSRIs were analysed in four different models (see Table 1 ).
CONFOUNDING FACTORS For each individual we calculated a score measuring the likelihood of redeeming at least one prescription for SSRIs. To do so we used a logistic regressions model which included SSRI prescription as the outcome factor, and birth year, gender, adopted, own contact to mental department (substance abuse, psychotic and/or schizophrenia, affective, depression, anxiety and post-traumatic stress, behaviour disorders, personality disorder, patient type, number of contacts), study participants ' use of psychopharmacological drugs (antipsychotics, anxiolytics, psychoanaleptics without SSRIs (including other types of antidepressant drugs), anti-epileptic drugs or drugs for substance dependence), all kinds of criminal offences, number of contacts to somatic department, place of living ing HR represents the effect on suicide attempt after redeeming the fi rst prescription of SSRIs. The repeated time-dependent covariant estimates the effect for any quarter during which the individual is exposed.
A crude estimate of the HR was calculated for each of the 50 strata. The estimates were plotted into a fi gure and inspected for trend by use of simple linear regression modelling. We used Proc Reg in SAS for this.
We tested for proportionality for SSRI by testing for time-dependent covariants of SSRI. We included an interaction term of SSRI and the logarithm of time and inspected its p-value. We found a p-value below 0.05, which indicates presents of non-proportionality. This was done for each stratum, and proportionality assumptions were not met for all strata. Strata with low values of PS were more likely to meet the assumptions.
Results
A total of 392,458 individuals were followed from turning 7.0 years of age and until suicide attempt or 31 December 2011. The mean follow-up time was 17.77 years (SD 3.00 (0.01 -21.99)), which gives a total of 6,973,647.7 follow-up years. A total of 45,902 (11.7%) redeemed a prescription for SSRIs during follow-up. The mean age when they redeemed the fi rst prescription for SSRIs was 21.17 years (SD 3.17 (7.64 -28.94), 14.92% were below 18 years old). A total of 6364 (1.62%) had a suicide attempt during follow-up. The mean age at the index suicide attempt was 19.38 years (SD 3.27 (10.07 -28.80), 35.86% were below 18 years old). During follow-up 2067 persons died (181 by suicide), and 30 of the attempters died by suicide. Among those who redeemed a prescription for SSRIs, 215 died, 43 of them by suicide and therefore only 23.8% had redeemed a prescription for SSRIs prior to the suicide.
A cross-table between SSRIs and suicide attempts is presented in Table 2 . The table shows that 4.2% of all the individuals redeeming a prescription for SSRIs were registered with a suicide attempt at some point later in life. Furthermore, 30 % of all the suicide attempters had redeemed at least one prescription for SSRIs earlier in their life.
The estimate of the risk of suicide attempt after redeeming the fi rst prescription for SSRIs is shown in Figure 1 . The fi gure is based on only 41,710 users and 41,710 non-users (matched reference group), as it was used the C statistic. It was found to be 0.729, which indicates acceptable ability to distinguish between SSRI users and non-users (23). We included the strata in the logistic regression with SSRI as the outcome and all the above-mentioned covariants. We found that some factors were still signifi cant, which indicates that some covariants were not suffi ciently adjusted for through the use of strata. They were therefore, together with the strata, included in all of the Cox regression models of the impact of SSRI on risk of suicide attempts. The factors were gender, depression, anxiety and post-traumatic stress, behaviour disorders, personality disorder, type of contact to psychiatric department, use of antipsychotics, contacts to somatic department, parental level of income and parental use of psychopharmacological drugs.
Analysis
Based on the cohort of individuals redeeming a prescription for SSRIs and a matched non-redeeming comparison group, we estimated the survival distribution function in order to estimate the risk of suicide attempt as a function of time. The comparison group was matched on the PS value (strata), and they were all in the study at the time when the user redeemed the fi rst prescription for SSRIs. The two cohorts were followed from the time when the fi rst prescription for SSRIs was redeemed until the time of suicide attempt or end of follow-up. We estimated the survival distribution function by using the Kaplan Meier method in Proc Lifetest in SAS. The procedure returns an estimate of survival (no suicide attempt) for every time interval and a confi dence interval, and based on that we calculate the risk of attempting suicide after starting on SSRIs.
The impact of SSRIs on the risk of suicide attempt was analysed by Cox proportional hazards models, which assume a constant hazard ratio (HR) across time, and by extended Cox models, which extend the Cox model to include time variation in covariants. We estimated the impact of SSRIs on risk of suicide attempts in four different dichotomized models. All the models are shown in Table 1 .
Model 1 is the simplest and returns an unadjusted estimate of the impact. Model 4 is the most complicated and returns an adjusted estimate of the impact. Model 4 models " reality " most realistically, as it assumes individuals to be exposed and unexposed in some time intervals (quarters of years).
Proc Phreg in SAS was used to perform regression analysis of the time-to-event data on the Cox proportional hazards model (24). Age was the time-unit. The procedure returns a HR, a p-value and a confi dence interval. The hazard is the risk of having a suicide attempt in the next time-unit, given not having had a suicide attempt until then. The HR is the ratio between hazards for exposed and unexposed to SSRIs. When SSRI use is analysed as a time-dependent covariant, the result- quartile 0.13, SD 0.08). The distribution of the propensity score was different for the two SSRI groups, but very low and very high values were represented in both groups. However, more very high values were represented in the SSRI-user group. A more detailed analysis of the propensity score is given in Appendix 1 to be found online at http://informahealthcare.com/doi/abs/ 10.3109/08039488.2015.1065291. The estimates from the Cox regression models are reported in Table 3 . In all models, prescription for SSRIs is a statistically signifi cant risk factor for suicide attempts. The effect of prescription for SSRIs is lowered in the adjusted analysis compared to the crude level. Model number 3 has the lowest AIC value and is therefore to be preferred in a statistical context, but does not represent the real world situation. Model 4 models the real world most correctly and is in many ways the preferred model. As can been seen, the risk is relatively high ( ∼ 5 times) in periods where the individual is exposed to SSRIs. The interpretation of the HR is the same for all the models, but an important difference is the way the exposure periods are modelled.
In Figure 2 estimates of HR (log(HR)) for each of the 50 strata are reported. A trend test showed signifi cantly decreasing estimates (log(HR)) with increasing strata (increasing likelihood of receiving treatment (SSRI)). The parameter value was estimated to Ϫ 0.00297 (t value: Ϫ 9.48, p value Ͻ 0.0001). not possible to fi nd qualifi ed non-users for all the users. The probability of having had a suicide attempt within 10 years after taking SSRIs is estimated to be around 7%. As can been seen from Figure 1 the risk increases considerably in the fi rst 3 months after the fi rst SSRI prescription. This analysis does not differentiate between individuals who have been prescribed SSRIs continuously and those whose prescriptions have stopped, and it cannot be used to prove causality. The fi gure tells us that individuals redeeming a prescription are at a much higher risk of suicide attempt within the fi rst months after redeeming the prescription compared to the matched reference group, but it does not tells us that the risk is high because of SSRIs. After approximately 1 year, the risk is almost the same for the two groups.
In order to draw the fi gure, it was necessary to exclude 4,192 SSRI users from the analysis as it was not possible to fi nd comparable non-SSRI users (with high PS value). The excluded users had the highest probability of redeeming a prescription, and Figure 2 shows that the group with the highest probability for redeeming has no negative impact from SSRI on the risk of suicide attempt. Therefore the fi gure might be slightly biased towards higher risk of suicide attempt.
The mean value of the propensity score was calculated for SSRI users and was 0.20 (lower quartile 0.10, median 0.14, upper quartile 0.24, SD 0.17) and for non-SSRI users 0.11 (lower quartile 0.06, median 0.09, upper might be a marker for those in high risk rather than a causal risk factor. In the most real-life model (model 4), the risk was estimated to be signifi cantly higher in the SSRI-user group. The signifi cant fi nding is probably due to the increased risk that we found in connection with the start up of SSRI treatment.
Limitations
Based on factors from registers, we modelled a propensity score for SSRIs (23). Propensity score methods can only account for measured confounding. Therefore it is still possible that unmeasured confounders (such as doctors ' decision to prescribe SSRIs to those most at risk for suicidal behaviour) have not been fully captured by the propensity scores included in this study. Low and high values of the PS were represented in both the non-SSRIs and SSRIs prescription group. We included the PS in our models as strata, and we found impact from SSRIs on the risk of suicide attempt. There are two possible explanations for our fi nding: either SSRIs have a real impact Figure 2 reports that individuals with the lowest indication for redeeming SSRIs (modelled by the propensity score) are in the highest risk for suicide attempts, after redeeming a prescription on SSRIs.
Discussion
Results short
In this analysis of time-to-event data, we estimate the risk of suicide attempt to be high in the fi rst 3 months after redeeming SSRIs as prescription drugs for adolescents. We used four different models to analyse the impact from SSRIs on the risk of suicide attempt. In all our models, redeeming of SSRIs was signifi cantly associated with suicide attempts, after trying to control for many important confounders that may bias impact, such as mental illnesses and severity of mental illness. As this study is an observational study, confounding by indication might still bias the impact from SSRIs on the risk of suicide attempt, and therefore we might have overestimated the real impact. We cannot exclude that SSRIs Table 3 . The impact of SSRIs on risk of suicide attempts -four different models.
Model
Impact on risk Note and interpretation of HR HR CI 1. Crude 3.10 * * 2.94 -3.27 Hazard for attempts is 3.1 times higher in the SSRIs group assuming exposed all the time during follow-up 2. Adjusted 1.54 * * 1.45 -1.63 Hazard for attempts is 54% higher in the SSRIs group assuming exposed all the time during follow-up 3. Adjusted time-varying 7.81 * * 7.32 -8.33
Hazard for attempts is 7.81 times higher in the SSRIs group, at the time of starting on SSRIs and never ending taking SSRIs 4. Adjusted repeated time-varying (Longitudinal exposure, SSRIs) 5.23 * * 4.82 -5.68 Hazard for attempts is 5.23 times higher in any quarter of a year when exposed to SSRIs * * p Ͻ 0.0001.
Fig. 2.
Unadjusted point estimates of hazard ratio for the 50 strata.
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of suicidality, and more suicide prevention centres around the country. It is diffi cult to estimate how many suicides and suicide attempts the project has prevented, and based on ecological studies, it is also diffi cult to analyse the interaction between treatment with SSRIs and treatment of suicidality. Other study designs are needed. Some researchers and clinicians have expressed concerns about restrictions on the use of SSRIs in children and adolescents, as a decrease in prescriptions might result in increasing rates of untreated depression, which again might lead to increasing rates of suicidal behaviour (28). Examinations of US and Dutch data have confi rmed this hypothesis (29), but a UK ecological study analysing the impact on the incidence of suicide and non-fatal selfharm from regulatory action in 2003 to restrict the use of SSRIs found no indication that a reduction in the use of SSRIs had led to an increase in suicidal behaviour (30). Other study designs are needed in order to document this association.
The purpose of this study was only to analyse the impact from SSRIs on the risk of suicide attempt; not to evaluate the benefi ts of treatment of depressed children and adolescents with SSRIs. A Cochrane review of 19 randomized controlled trials, cross-over trials and cluster trials comparing newer generations of antidepressants with placebo in children and adolescents gave no compelling evidence for the effectiveness of SSRI drugs. The review found some evidence that the drugs reduce depression symptoms but also that they increase the risk of suicide-related behaviours (ideation and attempts). Still, it is important to bear in mind that untreated depression in children and adolescents can raise the risk of suicide signifi cantly (31). As our study shows that the risk of suicide attempts is highest in the period after redeeming the fi rst prescription, we recommend that clinicians keep close contact with the patient, especially during that period, and to practice systematic risk assessment. A relatively new study using self-controlled cases found a peak in risk for suicide attempts, self-harm and ideation on the day of prescription. We found similar results. The study analysed in more detail the temporal relationship between SSRIs (or TCAs) and risk for suicidal behaviour, as they estimated incidence rate ratios for each week (32). They explain the fi ndings by an artefact of GP-recording behaviour, where an antidepressant is given as a consequence of a suicide-related event.
Our analysis of HR in each of the strata shows that the impact from SSRIs on the risk of suicide attempt is non-existent or very low for individuals with the highest likelihood of redeeming prescriptions for SSRIs. This fi nding needs to be replicated in other studies. Many different interpretations of the fi gure can be given. If the likelihood of prescribing SSRIs is high, more severe psychopathology is to be expected and therefore a higher on the risk of suicide attempt, or our modelling of the propensity score is insuffi cient as the PS approach does not balance unmeasured confounders. Suicidal ideation or behaviour may well be the distinct factor that triggers the prescription of SSRIs. Therefore we must expect our estimates of the impact from SSRIs on the risk of suicide attempt to be an absolute maximum estimate.
The outcome variable (suicide attempt) is created on the basis of recommendations suggested by a Danish research group. The variable does not include all the suicide attempts made by the entire cohort, as some suicide attempts may be incorrectly registered in the registers and therefore unknown to us (18). On the other hand, we are convinced that what we are analysing are real suicide attempts and not some other kind of event, e.g. accidents.
This study is very highly powered and is therefore capable of fi nding small effects from SSRIs on the risk of suicide attempt. High-powered studies offer many benefi ts but also some disadvantages, as very small or negligible effects become signifi cant associations, which may be falsely interpreted as important associations. To achieve the greatest effect, a suicide behaviour prevention strategy should focus on the strongest association with the most exposed individuals.
The best Danish estimate of incidence of suicide attempt in youths (15 -19 years) shows an increasing trend from 1990 ( ∼ 150 per 100,000) to 2004 ( ∼ 450 per 100,000), and then a falling trend until 2011 (to ∼ 200 per 100,000) (25). The estimates are based on records of treatment of suicide attempts in the somatic secondary health care system (26). During the period 2001 -2010, the number of SSRIs users in Denmark increased from ∼ 200,000 to 320,000 per year ( ∼ 56%). The prescription rate has increased in all age groups, including children and adolescents. In 2001 the number of SSRI users among children and adolescents (0 -17 years) was 1,731; and in 2010 the number of users was 5,700. Thus, this age group has the highest relative increase in prescriptions, although not the nominally highest prescription rate. The age group with most prescriptions is women above the age of 65; 16.1% of this group has been prescribed SSRIs within the last 12 months, compared to only 0.8% of girls and 0.4% of boys in the youngest age group (27).
As can been seen from the above, the last decade has seen a co-occurrence of an increased prescription rate for SSRIs and a fall in suicide attempts for the youngest age group. An ecological study might conclude that medical treatment of depression and anxiety lowers the risk of suicide attempts, but ecological studies have diffi culties documenting causality between factors. In the same period where SSRI users have increased, a national suicide prevention project has been implemented. The project has resulted in more knowledge of suicide behaviour and prevention, especially in young people, better treatment effect of treatment in that group. Individuals with a low propensity score and individuals with a high propensity score might be two different populations with significantly different baseline risks for suicide attempts. Individuals with high propensity scores might more often be diagnosed with mental illness in psychiatric departments, and might therefore have more access to support and treatment, whereas individuals with low propensity scores might be undiagnosed and not have the same access to support and treatment. This might result in different levels of risk for suicide attempts.
Conclusion
Our results are much in line with results from the metaanalysis (1 -4), but we can add that the risk of suicide attempt is highest for young people in the fi rst 3 months after redeeming their fi rst prescription for SSRIs. This risk is then lowered and almost the same for SSRI users and non-users. For individuals estimated as having low indications for the drug (based on our propensity score), the risk of suicide attempt is high if they are redeeming prescriptions on SSRIs. It is important to emphasize that in this study individuals are not randomized as to treatment with SSRIs, and therefore we might have reported biased estimates of the impact on risk for suicide attempts, as our design may have missed some explicit reason for redeeming a prescription of SSRIs. SSRIs might be a marker (non-causal risk factor) for those at high risk, rather than a causal risk factor, but we would still recommend systematic suicide risk assessment for children and young people during the period after redeeming the fi rst prescription.
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